MedTrace Logo

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

NCT05234606 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-04-12

No results posted yet for this study

Summary

This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4 expression.

Conditions

Interventions

DRUG

SBT6290

Escalating doses by subcutaneous (SC) injection in 21-day cycles

DRUG

SBT6290

Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles

DRUG

pembrolizumab

200 mg via intravenous (IV) injection in 21-day cycles

Sponsors & Collaborators

  • Silverback Therapeutics

    lead INDUSTRY

Principal Investigators

  • Natasha Angra, PharmD · Silverback Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2022-03-31
Completion
2022-03-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05234606 on ClinicalTrials.gov